Charles Michaud
Geen lopende functies
Vermogen: 23 639 $ op 31-05-2024
Loopbaan van Charles Michaud
Eerdere bekende functies van Charles Michaud
Bedrijven | Functie | Begin | Einde |
---|---|---|---|
AOBiome Therapeutics, Inc.
AOBiome Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology AOBiome Therapeutics, Inc. develops microbiome-targeted therapies for local, nasal and systemic inflammatory conditions. Its portfolio includes three clinical-stage programs, a Phase 2b study to treat patients with acne vulgaris, a Phase 2 trial to reduce elevated blood pressure, and a Phase 1b/2a clinical trial in allergic rhinitis, as well as earlier-stage preclinical programs targeting diverse inflammatory indications. The company was founded by Jamie Heywood, David Whitlock and Lenny Barshack in 2013 and is headquartered in Cambridge, MA. | Comptroller/Controller/Auditor | 01-04-2019 | 01-06-2020 |
Q32 BIO INC. | Comptroller/Controller/Auditor | 01-06-2020 | - |
Financieel Directeur/CFO | 17-11-2023 | - | |
Treasurer | 17-11-2023 | - |
Opleiding van Charles Michaud
University of Massachusetts | Undergraduate Degree |
Boston University | Masters Business Admin |
Statistieken
Internationaal
Verenigde Staten | 4 |
Israël | 2 |
Operationeel
Comptroller/Controller/Auditor | 2 |
Director of Finance/CFO | 1 |
Treasurer | 1 |
Sectoraal
Health Technology | 3 |
Consumer Services | 3 |
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Verwante bedrijven
Bedrijven in privébezit | 2 |
---|---|
Homology Medicines, Inc.
Homology Medicines, Inc. Pharmaceuticals: MajorHealth Technology Homology Medicines, Inc. is a clinical-stage genetic medicines company, which engages in the translation of proprietary gene editing and gene therapy technology into novel treatments for patients with rare genetic diseases. The company was founded in March 2015 and is headquartered in Bedford, MA. | Health Technology |
AOBiome Therapeutics, Inc.
AOBiome Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology AOBiome Therapeutics, Inc. develops microbiome-targeted therapies for local, nasal and systemic inflammatory conditions. Its portfolio includes three clinical-stage programs, a Phase 2b study to treat patients with acne vulgaris, a Phase 2 trial to reduce elevated blood pressure, and a Phase 1b/2a clinical trial in allergic rhinitis, as well as earlier-stage preclinical programs targeting diverse inflammatory indications. The company was founded by Jamie Heywood, David Whitlock and Lenny Barshack in 2013 and is headquartered in Cambridge, MA. | Health Technology |
- Beurs
- Insiders
- Charles Michaud
- Ervaring